SLC5A2 and type 2 diabetes mellitus: They found that dapagliflozin reduced intraglomerular pressure without increasing renal vascular resistance by lowering efferent arteriolar resistance, findings that potentially implicate different effects of SGLT2 inhibition on renal hemodynamic function in in older adults with T2D versus young adults with T1D [21].